– ARCALYST ® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth – – ARCALYST 2026 net product revenue expected to be $900 - $920 million – – ...
Since launch, more than 4,150 prescribers have written ARCALYST prescriptions for recurrent pericarditis. Kiniksa also provided updates on its development pipeline, noting that data from the Phase 2 ...
CEO Sanj Patel highlighted that Kiniksa achieved $137.8 million in net product revenue for ARCALYST during Q1 2025, marking a 75% increase year-over-year. This success was attributed to robust ...
– ARCALYST® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively – – ARCALYST 2024 net product revenue expected to be $360 - $380 million, ...
– Abiprubart (KPL-404) Phase 2 rheumatoid arthritis trial met the primary efficacy endpoint in Cohort 3 at the weekly dose level – "Strong execution to date has laid the foundation for the continued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results